CA2002218A1 - Neoglycoproteins, the preparation and use thereof - Google Patents

Neoglycoproteins, the preparation and use thereof

Info

Publication number
CA2002218A1
CA2002218A1 CA2002218A CA2002218A CA2002218A1 CA 2002218 A1 CA2002218 A1 CA 2002218A1 CA 2002218 A CA2002218 A CA 2002218A CA 2002218 A CA2002218 A CA 2002218A CA 2002218 A1 CA2002218 A1 CA 2002218A1
Authority
CA
Canada
Prior art keywords
neoglycoproteins
preparation
monosialolactose
disialolactose
hsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2002218A
Other languages
French (fr)
Other versions
CA2002218C (en
Inventor
Herbert Wiegand
Silke Bosslet
Klaus Bosslet
Hans H. Sedlacek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of CA2002218A1 publication Critical patent/CA2002218A1/en
Application granted granted Critical
Publication of CA2002218C publication Critical patent/CA2002218C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The synthesis and use of neoglycoproteins is described.
Monosialolactose and disialolactose are isolated from bovine colostrum and coupled by means of a coupling reagent to human serum albumin (HSA) as carrier protein.
These neoglycoproteins are suitable as vaccines and, moreover, as ligands for the localization and therapy of lectin-expressing tumor tissues.
CA002002218A 1988-11-05 1989-11-03 Neoglycoproteins, the preparation and use thereof Expired - Fee Related CA2002218C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3837623.7 1988-11-05
DE3837623A DE3837623A1 (en) 1988-11-05 1988-11-05 NEOGLYCOPROTEINS, THEIR PRODUCTION AND USE

Publications (2)

Publication Number Publication Date
CA2002218A1 true CA2002218A1 (en) 1990-05-05
CA2002218C CA2002218C (en) 2000-08-08

Family

ID=6366580

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002002218A Expired - Fee Related CA2002218C (en) 1988-11-05 1989-11-03 Neoglycoproteins, the preparation and use thereof

Country Status (12)

Country Link
EP (1) EP0368131B1 (en)
JP (1) JP2838147B2 (en)
KR (1) KR0162635B1 (en)
AT (1) ATE142229T1 (en)
AU (1) AU630634B2 (en)
CA (1) CA2002218C (en)
DE (2) DE3837623A1 (en)
DK (1) DK549589A (en)
ES (1) ES2093612T3 (en)
GR (1) GR3021111T3 (en)
IE (1) IE76312B1 (en)
PT (1) PT92187B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008203A (en) * 1995-07-14 1999-12-28 Glycotech Corp. Methods for treatment of EGF receptor associated cancers

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3840044A1 (en) * 1988-11-27 1990-06-07 Behringwerke Ag GLYCOSPHINGOLIPIDS WITH A COUPLABLE GROUP IN THE SPHINGOID PART, THEIR PRODUCTION AND USE
EP0646377A1 (en) * 1993-10-01 1995-04-05 LUANFARMA S.r.l. Albumin-conjugated tumour cell-free extracts, antigenic compositions comprising the same, related antibodies, and uses thereof
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557931A (en) * 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
DE3840044A1 (en) * 1988-11-27 1990-06-07 Behringwerke Ag GLYCOSPHINGOLIPIDS WITH A COUPLABLE GROUP IN THE SPHINGOID PART, THEIR PRODUCTION AND USE

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008203A (en) * 1995-07-14 1999-12-28 Glycotech Corp. Methods for treatment of EGF receptor associated cancers
US6281202B1 (en) 1995-07-14 2001-08-28 Glycotech Corp. Pharmaceutical compositions for treatment of EGF receptor associated cancers

Also Published As

Publication number Publication date
AU630634B2 (en) 1992-11-05
IE76312B1 (en) 1997-10-22
DK549589D0 (en) 1989-11-03
DK549589A (en) 1990-05-06
GR3021111T3 (en) 1996-12-31
JP2838147B2 (en) 1998-12-16
JPH02173000A (en) 1990-07-04
EP0368131A2 (en) 1990-05-16
AU4436889A (en) 1990-05-10
IE893548L (en) 1990-05-05
KR900007429A (en) 1990-06-01
KR0162635B1 (en) 1998-11-16
ATE142229T1 (en) 1996-09-15
PT92187B (en) 1995-06-30
DE58909720D1 (en) 1996-10-10
EP0368131A3 (en) 1990-12-19
PT92187A (en) 1990-05-31
CA2002218C (en) 2000-08-08
DE3837623A1 (en) 1990-05-10
EP0368131B1 (en) 1996-09-04
ES2093612T3 (en) 1997-01-01

Similar Documents

Publication Publication Date Title
AU5772886A (en) Novel procoagulant proteins
EP0759067A4 (en) Transforming growth factor alpha h1
NO884154D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE PREPARATIONS.
DK0733067T3 (en) N-terminally chemically modified protein preparations and methods
FI104255B1 (en) Method for the preparation of fusion proteins containing N-terminal fragments of human serum albumin
AU1130392A (en) Synthetic htlv-iii peptides, compositions and uses thereof
EP0345549A3 (en) Removal of protein a from antibody preparations
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
CA2098021A1 (en) Composition Used as a Therapeutic Agent Against Chronic Viral Hepatic Diseases
CA2149770A1 (en) Detection of hypoxia
AU3937289A (en) Hybrid protein c constructs and methods for their preparation
CA2002218A1 (en) Neoglycoproteins, the preparation and use thereof
GR3015890T3 (en) Novel peptides, their use as immuno suppressants and processes for their preparation.
CA2139518A1 (en) Antigenic regions of tlp complexes and antibodies against the same
EP0209284A3 (en) Anthraquinone derivatives
AU592023B2 (en) Synthetic peptide compounds producing antibodies binding to human ldh-c4
AU7633987A (en) The use of 15-deoxyspergualine as a pharmaceutical
EP0213595A3 (en) New transferrins and use thereof
AU2695588A (en) Peptides, a process for the preparation thereof, the use thereof for obtaining antibodies, and the use thereof for blocking pai 1 activity in human blood
CA2004387A1 (en) Cyclosporine binding protein and use in an assay for biologically-active cyclosporine
AU7422387A (en) Tumor necrosis factor alpha as treatment for infectious diseases
ZA905295B (en) Production of antigens by self-assembly of polypeptide components
AU7144787A (en) Tumor-associated antigen (mol wt 68,000-48000; 40,000-80000; 28000-32000; 16000-19000)
AU5790390A (en) A novel tumor associated antigen
AU2065488A (en) The preparation of antigens of human immunodeficiency virus type 1, and the use thereof as diagnostic and therapeutic agent

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed